Eternal Energy Past Earnings Performance
Past criteria checks 0/6
Eternal Energy's earnings have been declining at an average annual rate of -60.7%, while the Pharmaceuticals industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 23.8% per year.
Key information
-60.7%
Earnings growth rate
-60.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 23.8% |
| Return on equity | -66.5% |
| Net Margin | -12,741.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Eternal Energy makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5 | -653 | 40 | 0 |
| 30 Sep 23 | 10 | -390 | 48 | 0 |
| 30 Jun 23 | 13 | -201 | 49 | 0 |
| 31 Mar 23 | 13 | -63 | 51 | 0 |
| 31 Dec 22 | 13 | -73 | 58 | 0 |
| 30 Sep 22 | 8 | -36 | 53 | 0 |
| 30 Jun 22 | 4 | 6 | 51 | 0 |
| 31 Mar 22 | 3 | 160 | 44 | 0 |
| 31 Dec 21 | 4 | 195 | 30 | 0 |
| 30 Sep 21 | 4 | 220 | 31 | 0 |
| 30 Jun 21 | 3 | 147 | 36 | 0 |
| 31 Mar 21 | 3 | 53 | 43 | 0 |
| 31 Dec 20 | 3 | 5 | 50 | 0 |
| 30 Sep 20 | 3 | -13 | 50 | 0 |
| 30 Jun 20 | 3 | 47 | 53 | 0 |
| 31 Mar 20 | 3 | 41 | 54 | 0 |
| 31 Dec 19 | 3 | 94 | 55 | 0 |
| 30 Sep 19 | 3 | 89 | 55 | 0 |
| 30 Jun 19 | 5 | 99 | 54 | 0 |
| 31 Mar 19 | 5 | 39 | 53 | 0 |
| 31 Dec 18 | 5 | 56 | 53 | 0 |
| 30 Sep 18 | 5 | 69 | 53 | 0 |
| 30 Jun 18 | 4 | 47 | 54 | 0 |
| 31 Mar 18 | 4 | 79 | 56 | 0 |
| 31 Dec 17 | 3 | 46 | 56 | 0 |
| 30 Sep 17 | 3 | -32 | 49 | 0 |
| 30 Jun 17 | 3 | -130 | 133 | 0 |
| 31 Mar 17 | 3 | -144 | 124 | 0 |
| 31 Dec 16 | 3 | -146 | 117 | 0 |
| 30 Sep 16 | 2 | -139 | 118 | 0 |
| 30 Jun 16 | 4 | -84 | 28 | 0 |
| 31 Mar 16 | 4 | -86 | 29 | 0 |
| 31 Dec 15 | 4 | -103 | 29 | 0 |
| 30 Sep 15 | 4 | -65 | 35 | 0 |
| 30 Jun 15 | 3 | -27 | 38 | 0 |
| 31 Mar 15 | 3 | -17 | 37 | 0 |
| 31 Dec 14 | 4 | 0 | 37 | 0 |
| 30 Sep 14 | 5 | 18 | 32 | 0 |
| 30 Jun 14 | 5 | 19 | 24 | 0 |
| 31 Mar 14 | 5 | 17 | 29 | 0 |
| 31 Dec 13 | 4 | 12 | 29 | 0 |
| 30 Sep 13 | 5 | 62 | 38 | 0 |
| 30 Jun 13 | 5 | 62 | 44 | 0 |
Quality Earnings: EE-R is currently unprofitable.
Growing Profit Margin: EE-R is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EE-R is unprofitable, and losses have increased over the past 5 years at a rate of 60.7% per year.
Accelerating Growth: Unable to compare EE-R's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EE-R is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5.7%).
Return on Equity
High ROE: EE-R has a negative Return on Equity (-66.52%), as it is currently unprofitable.